Cancer therapy: Tumours switch to resist.
Where this comes from
- Record sourced from PubMed, PMID 23051745.
- Also identified by DOI 10.1038/nature11489 and PMC identifier PMC3681612.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Tumour cells can respond to targeted immune-cell therapies by losing proteins that mark them as being cancerous. Subverting this resistance mechanism may lead to more durable cancer-treatment strategies.